@article{article, title  = {{Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.}},

 publisher = {{Springer Verlag}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/91088 http://dx.doi.org/10.1007/s40273-015-0334-3 }},

 year = {{2016}},

 month = {{3}},

 author = {{Essat M and Tappenden P and Ren S and Bessey A and Archer R and Wong R and Lobo A and Hoque S}},

 doi = {{10.1007/s40273-015-0334-3}},

 journal = {{Pharmacoeconomics}},

 note = {{Accessed on 2025/10/31}}}